Physician profile
Peter Santalucia
NPI 1578561247
$8,194.25
in general payments reported to CMS, 2019-2025
28 companies · $881 in 2025
The $881 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $523 · 2021: $933 · 2022: $1,016 · 2023: $1,747 · 2024: $1,806 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,145 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,144.77 |
| Education | $289.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,457.33 | 2019-2025 | Ilumya |
| Abbvie INC. | $1,418.58 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Pfizer INC. | $702.54 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $696.56 | 2022-2025 | Sotyktu |
| Ucb, INC. | $611.33 | 2020-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $520.25 | 2019-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $475.23 | 2019-2025 | |
| Lilly USA, LLC | $443.88 | 2019-2024 | Taltz, Olumiant |
| Genzyme Corporation | $358.52 | 2019-2024 | |
| Galderma Laboratories, L.P. | $211.44 | 2019-2025 | Nemluvio |
| Amgen INC. | $210.25 | 2019-2025 | Otezla, Otezla |
| Celgene Corporation | $178.82 | 2019 | |
| Incyte Corporation | $158.24 | 2021-2025 | Opzelura |
| Genentech USA, INC. | $150.14 | 2024 | Xolair |
| Regeneron Healthcare Solutions, INC. | $99.21 | 2019-2025 | Dupixent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $99.00 | 2025 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Arcutis Biotherapeutics, INC. | $74.16 | 2023-2025 | Zoryve |
| Prugen, INC. Pharmaceuticals | $50.02 | 2019-2020 | |
| Dermavant Sciences, INC. | $38.88 | 2023 | Vtama |
| Vyne Pharmaceuticals INC. | $34.30 | 2020-2021 | |
| Helsinn Therapeutics (U.S.), INC. | $26.08 | 2019 | |
| Dermira, INC. | $20.65 | 2019 | |
| Genentech, INC. | $18.82 | 2023 | Erivedge |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.75 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.07 | 2025 | Spevigo |
| Taro Pharmaceuticals USA, INC. | $15.00 | 2019 | |
| Biofrontera INC. | $14.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Santalucia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.